Literature DB >> 27499349

Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.

Namrata Khurana1, Sudha Talwar1, Partha K Chandra2, Pankaj Sharma3, Asim B Abdel-Mageed1, Debasis Mondal2, Suresh C Sikka1.   

Abstract

Prostate cancer (PCa) cells utilize androgen for their growth. Hence, androgen deprivation therapy (ADT) using anti-androgens, e.g. bicalutamide (BIC) and enzalutamide (ENZ), is a mainstay of treatment. However, the outgrowth of castration resistant PCa (CRPC) cells remains a significant problem. These CRPC cells express androgen receptor (AR) and utilize the intratumoral androgen towards their continued growth and invasion. Sulforaphane (SFN), a naturally occurring isothiocyanate found in cruciferous vegetables, can decrease AR protein levels. In the present study, we tested the combined efficacy of anti-androgens and SFN in suppressing PCa cell growth, motility and clonogenic ability. Both androgen-dependent (LNCaP) and androgen-independent (C4-2B) cells were used to monitor the effects of BIC and ENZ, alone and in combination with SFN. Co-exposure to SFN significantly (p<0.005) enhanced the anti-proliferative effects of anti-androgens and downregulated expression of the AR-responsive gene, prostate specific antigen (PSA) (p<0.05). Exposure to SFN decreased AR protein levels in a time- and dose-dependent manner with almost no AR detected at 24 h with 15 µM SFN (p<0.005). This rapid and potent AR suppression by SFN occurred by both AR protein degradation, as suggested by cycloheximide (CHX) co-exposure studies, and by suppression of AR gene expression, as evident from quantitative RT-PCR experiments. Pre-exposure to SFN also reduced R1881-stimulated nuclear localization of AR, and combined treatment with SFN and anti-androgens abrogated the mitogenic effects of this AR-agonist (p<0.005). Wound-healing assays revealed that co-exposure to SFN and anti-androgens can significantly (p<0.005) reduce PCa cell migration. In addition, long-term exposures (14 days) to much lower concentrations of these agents, SFN (0.2 µM), BIC (1 µM) and/or ENZ (0.4 µM) significantly (p<0.005) decreased the number of colony forming units (CFUs). These findings clearly suggest that SFN may be used as a promising adjunct agent to augment the efficacy of anti-androgens against aggressive PCa cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27499349     DOI: 10.3892/ijo.2016.3641

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

Review 1.  Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators.

Authors:  Debasis Mondal; Devin Narwani; Shahnawaz Notta; Dawood Ghaffar; Nikhil Mardhekar; Syed S A Quadri
Journal:  Cancer Drug Resist       Date:  2021-03-19

2.  Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma.

Authors:  Jacob W Greenberg; Hogyoung Kim; Louis S Krane; Ahmed A Moustafa; Amrita Datta; Pedro C Barata; A Hamid Boulares; Asim B Abdel-Mageed
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

3.  PRL‑3 increases the aggressive phenotype of prostate cancer cells in vitro and its expression correlates with high-grade prostate tumors in patients.

Authors:  Donna R Edwards; Krzysztof Moroz; Haitao Zhang; David Mulholland; Asim B Abdel-Mageed; Debasis Mondal
Journal:  Int J Oncol       Date:  2017-11-20       Impact factor: 5.650

Review 4.  Epigenetic modulators as therapeutic targets in prostate cancer.

Authors:  Inês Graça; Eva Pereira-Silva; Rui Henrique; Graham Packham; Simon J Crabb; Carmen Jerónimo
Journal:  Clin Epigenetics       Date:  2016-09-15       Impact factor: 6.551

5.  Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.

Authors:  Namrata Khurana; Hogyoung Kim; Partha K Chandra; Sudha Talwar; Pankaj Sharma; Asim B Abdel-Mageed; Suresh C Sikka; Debasis Mondal
Journal:  Oncol Rep       Date:  2017-08-30       Impact factor: 3.906

Review 6.  Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer.

Authors:  Namrata Khurana; Suresh C Sikka
Journal:  Cancers (Basel)       Date:  2018-09-25       Impact factor: 6.639

7.  Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells.

Authors:  Namrata Khurana; Partha K Chandra; Hogyoung Kim; Asim B Abdel-Mageed; Debasis Mondal; Suresh C Sikka
Journal:  Antioxidants (Basel)       Date:  2020-01-12

Review 8.  Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets.

Authors:  Fabrizio Fontana; Michela Raimondi; Monica Marzagalli; Alessandro Di Domizio; Patrizia Limonta
Journal:  Cells       Date:  2020-02-18       Impact factor: 6.600

9.  The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor.

Authors:  Catalina Carrasco-Pozo; Kah Ni Tan; Tayner Rodriguez; Vicky M Avery
Journal:  Int J Mol Sci       Date:  2019-10-29       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.